Jeffrey Goldfarb is the U.S. Editor of Breakingviews. Based in New York, he coordinates coverage in the region, while frequently writing about Wall Street, private equity, M&A and the media and tech industries. Before becoming a columnist in 2007, he covered banking, mergers, international trade, healthcare and the internet for Reuters and BNA. From London, Jeffrey led the European corporate finance team for Reuters and coverage of the continent's media sector. He has a master's in journalism from Columbia University and a bachelor's degree in finance from The George Washington University. Follow Jeffrey on Twitter @jgfarb
- Tel: +1 646 223 6098
- E-mail: firstname.lastname@example.org
The U.S. pharma giant is buying Stemcentrx, an eight-year-old cancer-drug developer backed by the blue-chip Founders Fund. Valued at $5 bln last fall, it was among Silicon Valley startups tarnished by recent markdowns. The sale suggests some hyped firms can still live the fantasy.
Presidential candidate Ted Cruz tapped the former Hewlett-Packard boss to be his running mate if he can somehow win the Republican nomination. The math, after a five-state sweep by front-runner Donald Trump, is about as compelling as Fiorina’s calculus for HP’s purchase of Compaq.
Joining forces with Tudor Pickering, as is being discussed, would combine energy expertise with restructuring know-how and global reach in one shot. A Goldman Sachs imprimatur also could help unite the boutique cultures. The logic suggests there’s more to it than just doing a deal.
- EMC deal math has snowball's chance for Dell
- Swallow IMF's medicine with spoonful of bank sugar
- Disney leadership hitch evokes Eisner era
- David Tepper exposes tax-avoidance paradox
- Disney's fairytale CEO plan gets twist in ending
- Anbang risks a Year of the Stalking Horse
- Starwood can easily answer the $4.64 question